HALIFAX, Nova Scotia, May 31, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (TSX:IMV)
(OTCQX:IMMVD), a clinical stage immunotherapy company, today announced that its common shares have been approved for listing on the
Nasdaq Capital Market under the symbol "IMV." Trading will commence as early as Friday, June 1, 2018. The Corporation will retain
its listing on the Toronto Stock Exchange under the symbol "IMV" and the company's common shares will continue to trade on the
OTCQX under the symbol “IMMVD” until trading on the Nasdaq commences.
Frederic Ors, IMV
Chief Executive Officer, commented, “On the heels of recent progress we have made in positioning and validating IMV’s unique
value proposition in immuno-oncology, listing on Nasdaq affords us the opportunity to attract more institutional investors, broaden
our shareholder base, and improve liquidity. We celebrate this milestone and look forward to continuing our track record of
clinical progress and corporate advancement.”
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more
broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of
immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of
action that enables the reprogramming of immune cells in vivo, which are aimed at generating powerful new synthetic
therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell activating immunotherapy that combines the utility of the
platform with a target: survivin. IMV is currently conducting three Phase 2 studies with Incyte and Merck assessing DPX-Survivac as
a combination therapy in ovarian cancer and diffuse large B-cell lymphoma. Connect at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under applicable Canadian and U.S. securities law. All
information that addresses activities or developments that we expect to occur in the future is forward-looking information.
Although the Corporation believes the forward-looking statements in this press release are reasonable, it can give no
assurance that the expectations and assumptions in such statements will prove to be correct. The Corporation cautions investors
that any forward-looking statements by the Corporation are not guarantees of future results or performance, and that actual results
may differ materially from those in forward-looking statements as a result of various factors, including, but not limited to, the
matters discussed under “Risk Factors and Uncertainties” in IMV’s Annual Information Form filed on March 20, 2018. IMV Inc.
assumes no responsibility to update forward-looking statements in this press release except as required by law.
Contacts for IMV:
MEDIA
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONS
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: info@imv-inc.com
Patti Bank, Managing Director, Westwicke Partners
O: (415) 513-1284
T: (415) 515-4572 E: patti.bank@westwicke.com
